The TEAD1 Knockout BEAS-2B Cell Line is a CRISPR/Cas9-edited knockout cell line with targeted disruption of the TEAD1 locus in the BEAS-2B human bronchial epithelial cell line. This loss-of-function model eliminates endogenous TEAD1 protein, providing a defined system to dissect TEAD1-dependent transcriptional programs in Hippo signaling. The genetically modified population is suitable for diverse biochemical and cell-based assays.
The BEAS-2B parental line is an SV40 large T antigen-immortalized human bronchial epithelial cell line that retains key characteristics of normal airway epithelium, including polarized monolayer formation and epithelial marker expression. Widely used in respiratory research, BEAS-2B serves as a model for studying barrier function, epithelial-to-mesenchymal transition, and early neoplastic transformation. Its nontumorigenic phenotype and lung origin make it particularly appropriate for investigating Hippo pathway contributions to airway homeostasis and oncogenesis.
TEAD1 is a TEA domain transcription factor that functions as the primary DNA-binding component for the Hippo pathway co-activators YAP1 and WWTR1 (TAZ). Canonical Hippo signaling employs the kinases MST1/2 and LATS1/2 to phosphorylate YAP1/WWTR1, promoting their cytoplasmic retention. When the pathway is inactivated, dephosphorylated YAP1/WWTR1 accumulate in the nucleus and associate with TEAD1 to drive transcription of target genes such as CTGF, CYR61, AXL, MYC, and BIRC5, which promote proliferation and inhibit apoptosis. TEAD1 activity is further fine-tuned by interactions with VGLL family proteins, including the repressor VGLL4. Thus, TEAD1 represents a critical node linking Hippo pathway activity to transcriptional outcomes.
In the BEAS-2B airway epithelial background, TEAD1 knockout enables dissection of cell-autonomous Hippo/TEAD signaling functions in lung homeostasis and disease. Loss of TEAD1 abrogates YAP1/WWTR1-mediated transcription, permitting separation of TEAD1-specific roles from those of other TEAD factors. This model is valuable for studying epithelial proliferation, differentiation, barrier integrity, and responses to injury, as well as for examining how aberrant Hippo activation drives hyperplasia and malignant conversion in respiratory epithelia.
Applications include western blot and RT-qPCR for verifying TEAD1 deletion and monitoring target gene expression, luciferase reporter assays to quantify Hippo pathway activity, and co-immunoprecipitation to analyze residual protein complexes. Functional phenotypes can be assessed with proliferation and invasion assays. Importantly, this knockout cell line serves as an ideal negative control for high-throughput screening of YAP/TEAD interaction inhibitors or TEAD palmitoylation blockers, offering a genetically defined background for compound validation. For technical inquiries, contact Ascent Research.
